2023
Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, Ciplea A, Cooper J, Fabian M, Hale T, Jacobs D, Kakara M, Krysko K, Longbrake E, Marcus J, Repovic P, Riley C, Romeo A, Rutatangwa A, West T, Hellwig K, LaHue S, Bove R. Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Annals Of Clinical And Translational Neurology 2023, 10: 2053-2064. PMID: 37675826, PMCID: PMC10647007, DOI: 10.1002/acn3.51893.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderDisease-modifying therapiesMultiple sclerosisAnti-CD20 monoclonal antibody therapyCD20 IgG1 monoclonal antibodyInfant development outcomesPatient questionnaire responsesRelative infant doseOptica spectrum disorderMonoclonal antibody therapyIgG1 monoclonal antibodyMature breastmilkClinical relapseDisease activityInfant doseMAb therapyInfant outcomesAntibody therapyPostpartum womenPostpartum periodMedical recordsInfant growthPostpartum treatmentNeurological conditionsBreastmilk
2021
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data
Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, Diallo F, Ricci A, Riley CS, De Jager PL, Farber R, Wesley SF, Collaborative M. Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis And Related Disorders 2021, 57: 103433. PMID: 34923427, PMCID: PMC8638239, DOI: 10.1016/j.msard.2021.103433.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderSelf-reported side effectsNeuroinflammatory diseasesSARS-CoV-2Multiple sclerosisSide effectsSARS-CoV-2 vaccine trialsCross-sectional observational studySafety/tolerability dataAsymptomatic control populationNeurologist-confirmed diagnosisRadiologic disease activityRecurrent neurologic symptomsSignificant vaccine hesitancyOptica spectrum disorderAntibody-mediated diseasesVaccine side effectsViral vector vaccinesReal-world evidenceMultiple academic centersNID patientsUnvaccinated patientsVaccines surveyDisease activityNeurologic events
2020
Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees
Hua LH, Obeidat AZ, Longbrake EE. Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees. Multiple Sclerosis And Related Disorders 2020, 44: 102296. PMID: 32585616, PMCID: PMC8023409, DOI: 10.1016/j.msard.2020.102296.Peer-Reviewed Original ResearchConceptsNeuroimmune diseasesFellowship trainingRecent traineesTraditional clinic-based modelNeuromyelitis optica spectrum disorderOptica spectrum disorderDiagnosis of MSNational MS SocietyClinic-based modelFellowship training experienceMS SocietyMultiple sclerosisCurrent medical practiceBasic immunologyUS training programsTraining programNeuro-rehabilitationSubspecialty certificationOutcomesMedical practiceDiseasePractice outcomesCurrent traineesDidactic trainingFellowship experience